Superluminal Medicines secures $60m to advance rare obesity therapy

Superluminal Medicines has completed a $60m Series B round to support its research into therapies for rare genetic forms of obesity. Superluminal Medicines will use the proceeds to advance its MC4R agonist candidate into Phase I trials by 2026. Superluminal’s MC4R agonist is being developed for rare genetic forms of obesity, including BBS and hypothalamic obesity. Credit: New Africa / Shutterstock.com. US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity. The funding was led by BVF Partners, with participation from new…

Source: Pharmaceutical Technology